Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 15;12(5):2267-2280.
eCollection 2020.

Prognostic value of preoperative serum bilirubin levels in ovarian cancer

Affiliations

Prognostic value of preoperative serum bilirubin levels in ovarian cancer

Xiao-Xue Xi et al. Am J Transl Res. .

Abstract

Bilirubin is a promising prognostic factor for non-liver disease-related deaths in various cancers. We investigated the association between preoperative serum bilirubin levels and oncological outcomes in patients with ovarian cancer. We retrospectively analyzed the clinical data of 282 patients with epithelial ovarian carcinoma (EOC), and grouped them according to optimal threshold values of total bilirubin (TBIL), direct bilirubin (DBIL), and indirect bilirubin (IBL) measured by receiver operating characteristic curve analysis. Univariate and multivariate Cox proportional hazards regression analyses were used to evaluate various parameters that might affect overall survival (OS) and progression-free survival (PFS) in patients with EOC. The optimal cutoff values for TBIL, DBIL, and IBIL levels were 9.65 µmol/L, 2.95 µmol/L, and 6.75 µmol/L, respectively. Increased TBIL, DBIL, and IBIL levels correlated with the serum carbohydrate antigen (CA)-125 levels, International Federation of Gynecology and Obstetrics stage, and pathological differentiation (all P<0.05). Univariate analysis revealed longer OS and PFS in patients with high TBIL (≥9.65 µmol/L) and IBIL (≥6.75 µmol/L) levels (P<0.05). Multivariate analysis showed that patients with high IBIL levels (≥6.75 µmol/L) had significantly longer OS and PFS than those with low IBIL levels (<6.75 µmol/L) [hazard ratio (HR) = 0.333, 95% confidence interval (CI): 0.123~0.904, P<0.05; HR = 1.814, 95% CI: 1.169~2.816, P<0.05]. Therefore, IBIL is a potential independent prognostic factor for OS and PFS in patients with EOC. The higher the IBL level, the better the prognosis of patients with EOC.

Keywords: Bilirubin; epithelial ovarian carcinoma; overall survival; prognosis; progression-free survival.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
ROC curve to build a predictive model for risk of ovarian cancer. TBIL, IBL, DBIL, preoperative CA125 level, tumor size and age were selected according to the ROC curve to obtain the optimal interception point (9.65 µmol/L, 6.75 µmol/L, 2.95 µmol/L, 124 U/mL, 9 cm and 65 years old) for the analysis of influencing factors of OS.
Figure 2
Figure 2
Univariate analysis of overall survival in EOC patients. Kaplan-Meier survival curves showing the effects of TBIL and IBL for OS and PFS. TBIL and IBL survival curves were statistically significant for OS (P-value = 0.001, chi-square = 12.020; P-value = 0.002, chi-squared = 9.384) and for PFS (P-value = 0.000, chi-squared = 15.990). P-value = 0.001, chi-squared = 11.356).

Similar articles

Cited by

References

    1. White KM, Seale H, Harrison R. Enhancing ovarian cancer care: a systematic review of guideline adherence and clinical variation. BMC Public Health. 2019;19:296. - PMC - PubMed
    1. Kumar S, Long J, Kehoe S, Sundar S, Cummins C. Quality of life outcomes following surgery for advanced ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2019;29:1285–1291. - PubMed
    1. Canaz E, Grabowski JP, Richter R, Braicu EI, Chekerov R, Sehouli J. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: an analysis of five prospective phase II/III trials of NOGGO metadata base. Gynecol Oncol. 2019;154:539–546. - PubMed
    1. Christophersen MK, Hogdall C, Hogdall E. The prospect of discovering new biomarkers for ovarian cancer based on current knowledge of susceptibility loci and genetic variation (Review) Int J Mol Med. 2019;44:1599–1608. - PubMed
    1. Kawakami E, Tabata J, Yanaihara N, Ishikawa T, Koseki K, Iida Y, Saito M, Komazaki H, Shapiro JS, Goto C, Akiyama Y, Saito R, Saito M, Takano H, Yamada K, Okamoto A. Application of artificial intelligence for preoperative diagnostic and prognostic prediction in epithelial ovarian cancer based on blood biomarkers. Clin Cancer Res. 2019;25:3006–3015. - PubMed

LinkOut - more resources